| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | p55; CD25; IL2R; IMD41; TCGFR; IDDM10 |
| WB Predicted band size | 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human IL2RA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL2RA抗体的3篇代表性文献的简要总结(示例格式)：
---
1. **文献名称**: *IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility*
**作者**: Todd JA, et al.
**摘要**: 通过全基因组关联研究(GWAS)发现IL2RA基因多态性与1型糖尿病和多发性硬化的易感性相关，提示IL2RA在自身免疫中的关键调控作用。
2. **文献名称**: *Daclizumab therapy for multiple sclerosis*
**作者**: Bielekova B, et al.
**摘要**: 研究抗IL2RA单克隆抗体(达克珠单抗)治疗多发性硬化的临床试验，显示其通过阻断T细胞激活降低疾病复发率，但可能引发免疫相关副作用。
3. **文献名称**: *Soluble IL-2RA as a biomarker in autoimmune diseases*
**作者**: Malek TR.
**摘要**: 综述指出可溶性IL-2受体α(sIL-2RA)在类风湿性关节炎、系统性红斑狼疮等疾病中作为炎症标志物的潜力，与其在Treg细胞功能失调中的机制相关。
---
**注**：以上为示例，具体文献请通过PubMed或Google Scholar检索关键词(如“IL2RA antibody”“IL2RA autoimmune”“soluble IL2RA”)获取最新研究。
Interleukin-2 receptor alpha (IL2RA), also known as CD25. is a key component of the high-affinity interleukin-2 (IL-2) receptor complex. IL-2 is a cytokine critical for T-cell proliferation, differentiation, and immune regulation. The IL-2 receptor exists in three forms: low-, intermediate-, and high-affinity, with the high-affinity receptor comprising IL2RA (α-chain), IL2RB (β-chain), and IL2RG (γ-chain). IL2RA is primarily expressed on regulatory T cells (Tregs), activated effector T cells, and some innate immune cells, playing a dual role in promoting immune activation and tolerance.
Antibodies targeting IL2RA have significant research and clinical relevance. In basic research, they are used to study Treg function, IL-2 signaling pathways, and immune homeostasis. Clinically, IL2RA antibodies like daclizumab (a humanized monoclonal antibody) were historically used to modulate immune responses in autoimmune diseases and organ transplantation by blocking IL-2 binding to T cells. However, safety concerns led to their discontinuation. IL2RA is also a biomarker in autoimmune diseases (e.g., type 1 diabetes, multiple sclerosis) and cancers, where its expression correlates with disease activity or prognosis. Current therapeutic strategies explore IL2RA-targeting agents to selectively deplete Tregs in cancer immunotherapy or enhance Treg activity in autoimmunity. Challenges remain in balancing efficacy and toxicity due to IL-2's pleiotropic roles.
×
